| Literature DB >> 31251831 |
Nozomi Abe1, Hiroki Yasudo1, Reiji Fukano1, Tamaki Nakamura1, Seigo Okada1, Hiroyuki Wakiguchi1, Fumiko Okazaki1, Komei Shirabe2, Shoichi Toda2, Reiko Okamoto2, Kazunobu Ouchi3, Shouichi Ohga1,4, Shunji Hasegawa1.
Abstract
BACKGROUND: Respiratory viral and mycoplasma infections are associated with childhood asthma exacerbations. Here, we explored epidemiologic profile of causative pathogens and possible factors for exacerbation in a single center over a three-year period.Entities:
Keywords: asthma; enterovirus D68; epidemiology; hospitalization; respiratory syncytial virus; rhinovirus
Mesh:
Year: 2019 PMID: 31251831 PMCID: PMC7167852 DOI: 10.1111/pai.13102
Source DB: PubMed Journal: Pediatr Allergy Immunol ISSN: 0905-6157 Impact factor: 6.377
Clinical characteristics, asthma exacerbation intensity, and asthma severity in the total subjects and the asthmatic subjects with single infection of RV and RSV
| Median (range) | Total (n = 216) | RV (n = 87) | RSV (n = 10) |
RV vs RSV |
|---|---|---|---|---|
| Age (mo: months, y: years) | 3.4 (6 mo‐17 y) | 4.5 (6 mo‐13 y) | 1.6 (8 mo‐6 y) | .008 |
| Body temperature (°C) | 37.5 (36.0‐40.0) | 37.5 (36.1‐40.4) | 37.3 (37.0‐39.1) | .916 |
| SpO2 (%) | 94 (84‐100) | 94 (84‐100) | 96 (94‐100) | .109 |
| WBC (×109/L) | 12.0 (3.4‐32.8) | 12.8 (4.7‐32.8) | 11.0 (5.1‐18.8) | .558 |
| CRP (mg/dL) | 0.97 (0.01‐14.86) | 0.82 (0.01‐12.16) | 0.62 (0.03‐14.86) | .309 |
| Total IgE (IU/mL) | 207 (4‐11,800) | 508 (4‐5,440) | 103 (10‐1,970) | .254 |
| Mite IgE (UA/mL) | 19.0 (0.1‐100) | 90.1 (0.1‐100) | 0.1 (0.1‐100) | .002 |
| Duration of hospitalization (days) | 10 (2‐75) | 9 (2‐56) | 10 (6‐14) | .999 |
| Exacerbation severity | ||||
| Mild | 21 (10%) | 5 (6%) | 1 (10%) | .824 |
| Moderate | 146 (68%) | 59 (68%) | 6 (60%) | |
| Severe | 49 (22%) | 23 (26%) | 3 (30%) | |
| BA control | ||||
| Good | 138 (64%) | 48 (55%) | 9 (90%) | .098 |
| Partial | 28 (13%) | 24 (28%) | 1 (10%) | |
| None | 50 (23%) | 15 (17%) | 0 (0%) | |
Abbreviations: BA, bronchial asthma; CRP, C‐reactive protein; IgE, immunoglobulin E; RSV, respiratory syncytial virus; RV, rhinovirus; SpO2, oxygen saturation of peripheral artery; WBC, white blood cell.
P < 0.05.
Figure 1The relationship between causative viruses and/or Mycoplasma pneumoniae infection and asthma exacerbation
Clinical characteristics, asthma exacerbation intensity, and asthma severity in the asthmatic patients with single infection and superinfection
| Median (range) | Single infection (n = 136) | Superinfection (n = 35) |
|
|---|---|---|---|
| Age (mo: months, y: years) | 4.0 (6 mo‐14 y) | 1.4 (6 mo‐5.9 y) | <.001 |
| Body temperature (°C) | 37.5 (36.1‐40.4) | 37.7 (36.0‐40.0) | .372 |
| SpO2 (%) | 94 (84‐100) | 95 (84‐99) | .333 |
| WBC (×109/L) | 12.2 (3.6‐32.8) | 11.8 (5.6‐24.0) | .853 |
| CRP (mg/dL) | 0.93 (0.01‐14.86) | 1.14 (0.02‐7.28) | .772 |
| Total IgE (IU/mL) | 332 (4‐7,070) | 60 (4‐3,500) | .152 |
| Mite IgE (UA/mL) | 53.2 (0.1‐100) | 0.34 (0.1‐100) | <.001 |
| Duration of hospitalization (d) | 9.5 (2‐56) | 10 (2‐26) | .330 |
| Exacerbation severity | |||
| Mild | 10 (6%) | 5 (14%) | .413 |
| Moderate | 93 (51%) | 23 (66%) | |
| Sever | 33 (18%) | 7 (20%) | |
| BA control | |||
| Good | 85 (62%) | 25 (71%) | .163 |
| Partial | 31 (23%) | 9 (26%) | |
| None | 20 (15%) | 1 (3%) | |
Figure 2The relationship between asthma exacerbation and virus and/or Mycoplasma pneumoniae distribution based on the month of admission
Causative pathogens in the hospitalized patients on multiple admissions
| Patient | Age (mo) | 1st admission | 2nd (mo) | 3rd (mo) | 4th (mo) | 5th (mo) |
|---|---|---|---|---|---|---|
| 1 | 8 | RSV + Cox | hMPV (12) | |||
| 2 | 8 | PIV | RSV (1) | |||
| 3 | 11 | RV type C + AdV | RV type C + EBV (6) | |||
| 4 | 12 | Negative | RV type A (5) | |||
| 5 | 12 | RV type C + PIV | RV type C + PIV (1) | |||
| 6 | 14 | RV type C | RV (9) | |||
| 7 | 16 | RV type C + RSV | RV type C (24) | |||
| 8 | 17 | EV‐D68 | RV type C (15) | |||
| 9 | 20 | Negative | AdV (17) | |||
| 10 | 24 | RV | RV type C + PIV (0.5) | |||
| 11 | 29 | RV type A | Others (1) | |||
| 12 | 29 | RV type C | RV type C (24) | |||
| 13 | 37 | RV type A | RV type C (12) | |||
| 14 | 45 | RV type A | RV type C (10) | |||
| 15 | 55 | RV type A | RV type B (19) | |||
| 16 | 72 | RV type C | RV type C (0.75) | |||
| 17 | 82 | RSV | RV type C (15) | |||
| 18 | 84 | RV type A | RV type A (16) | |||
| 19 | 90 | RV type A | RV type A (3) | |||
| 20 | 129 | RV type C | RV type C (4) | |||
| 21 | 202 | Negative | Negative (13) | |||
| 22 | 8 | hMPV + PIV | RSV (3) | RV type B + RSV+Cox (4) | ||
| 23 | 17 | Negative | RV type C (12) | RV type A (6) | ||
| 24 | 20 | RV type A + AdV +Echo | EV‐D68 (2) | RV type A (11) | ||
| 25 | 56 | Myco | RV type A (20) | HCoV (2) | ||
| 26 | 99 | RV type C | RV type A (9) | RV type A (8) | ||
| 27 | 11 | hMPV + Adeno | Negative (2) | Negative (2) | RV type C (6) | |
| 28 | 14 | RV type C | Flu type A (3) | RV type C (1) | hMPV (4) | |
| 29 | 24 | PIV + Myco | RV type C (4) | HCoV (14) | hMPV (2) | |
| 30 | 153 | Negative | Negative (6) | Negative (3) | HCoV (15) | |
| 31 | 8 | RV type A | Negative (1) | RV type C (3) | Myco (8) | RV type A(9) |
Months in 2nd, 3rd, 4th, and 5th represent the number of months showing the interval from the previous admission.
Abbreviations: AdV, adenovirus; Cox, Coxsackie virus; EBV, Epstein‐Barr virus; EV‐D68, enterovirus D68; Flu, influenza virus; HCoV, human coronavirus; hMPV, human metapneumovirus; Myco, mycoplasma; others, other virus; PIV, parainfluenza virus; RSV, respiratory syncytial virus; RV, rhinovirus.
Figure 3The relationship between hospital admission due to asthma exacerbation and infection with EV‐D68